Something seems afoot with the EU approval of Janssen Pharmaceutical Cos.’s controversial new drug for treatment-resistant depression Spravato (esketamine).
The European Medicines Agency has received “written interventions” from third parties relating to the agency’s October recommendation that the drug...






